Radiation after surgery keeps high-risk prostate cancer at bay

An analysis of data involving more than 2,000 patients from 17 U.S. institutions demonstrates that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy were less likely to have a recurrence of disease.

What's more, men whose cancer persists after surgery were less likely to see the cancer spread if they receive radiation (salvage therapy). These are the conclusions of a study presented today at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

“Our analysis gives us a robust picture of the national experience in treating these high-risk prostate cancers,” said Eric M. Horwitz, M.D., clinical director of the radiation oncology department at Fox Chase Cancer Center, Philadelphia, and lead author of the study.

For the study, data from 2,183 men who underwent radiation therapy after radical prostatectomy were available for analysis.

“This is the first time we've applied the new method of defining success to such a large sampling,” explained Horwitz. “The results are even more dramatic in favor of post-operative radiation when compared to the old formula. Given our findings, I expect we'll see more men receive and benefit from radiation after prostatectomy for men with high-risk prostate cancer.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MR1 molecule and vitamin B6 could unlock new paths for cancer immunotherapy